Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1500648800HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Merck Serono ditches another multiple sclerosis candidate

17.06.2014 / Scripintelligence

ONO-4641 is a sphingosine-1-phosphate (S1P) receptor agonist, like Novartis's Gilenya, which was launched in 2010. It met its primary endpoint of a reduction in the cumulative number of MRI lesions in a 407-patient Phase II trial in relapsing-remitting…

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: